MedTrace Logo

AI-Driven Early Detection of Skin Cancer

NCT07144306 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-09-26

No results posted yet for this study

Summary

This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.

Conditions

  • Skin Cancer Melanoma

Interventions

DIAGNOSTIC_TEST

Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Nuvana Healthcare LTD

    lead INDUSTRY

Principal Investigators

  • Aryan Chaudhary, · Scientific Advisor / Co-Founder, Nuvana Healthcare

Eligibility

Min Age
18 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2025-12-01
Completion
2026-01-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07144306 on ClinicalTrials.gov